EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 37 / Numéro 3 (Mars 2021) Med Sci (Paris), 37 3 (2021) 235-241 Références
Open Access
Numéro
Med Sci (Paris)
Volume 37, Numéro 3, Mars 2021
Page(s) 235 - 241
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021009
Publié en ligne 19 mars 2021
  1. Larrey D.. Foie, médicaments et agents chimiques. Gastroenterol Clin Biol 2009 ; 33 : 1136–1146. [PubMed] [Google Scholar]
  2. Chiew AL, Gluud C, Brok J, et al. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018 Feb. CD003328. [Google Scholar]
  3. Bénichou C.. Criteria of drug-induced liver disorders. J Hepatol 1990 ; 11 : 272–276. [CrossRef] [PubMed] [Google Scholar]
  4. Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 2013 ; 17 : 547–564. [Google Scholar]
  5. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014 ; 109 : 950–966. [Google Scholar]
  6. Megarbane B, Deye N, Baud F. Foie toxique : mécanismes lésionnels et thérapeutiques pharmacologiques spécifiques. Réanimation 2007 ; 16 : 632–642. [Google Scholar]
  7. Russmann S, Kullak-Ublick G, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009 ; 16 : 3041–3053. [PubMed] [Google Scholar]
  8. Gunawan BK, Liu Z, Han D, et al. c-Jun N-Terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006 ; 131 : 165–178. [PubMed] [Google Scholar]
  9. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (atp) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997 ; 185 : 1481–1486. [PubMed] [Google Scholar]
  10. Uetrecht J.. Immunoallergic Drug-induced liver injury in humans. Semin Liver Dis 2009 ; 29 : 383–392. [Google Scholar]
  11. Touloukian J, Kaplowitz N. Halothane-induced hepatic disease. Semin Liver Dis 1981 ; 1 : 134–142. [Google Scholar]
  12. Gunawan BK, Kaplowitz N. mechanisms of drug-induced liver disease. Clin Liver Dis 2007 ; 11 : 459–475. [Google Scholar]
  13. Kaplowitz N.. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002 ; 22 : 137–144. [Google Scholar]
  14. Kaplowitz N.. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005 ; 4 : 489–499. [Google Scholar]
  15. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology 2013 ; 144 : 1419–25e3. [PubMed] [Google Scholar]
  16. Mosedale M, Watkins PB. Understanding idiosyncratic toxicity: lessons learned from drug-induced liver injury. J Med Chem 2020; 63 : 6436–61. [PubMed] [Google Scholar]
  17. Kleiner DE. The histopathological evaluation of drug-induced liver injury. Histopathology 2017 ; 70 : 81–93. [PubMed] [Google Scholar]
  18. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004 ; 36 : 301–312. [PubMed] [Google Scholar]
  19. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 2012 ; 44 : 88–106. [PubMed] [Google Scholar]
  20. Han D, Dara L, Win S, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci 2013 ; 34 : 243–253. [Google Scholar]
  21. Séguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003 ; 3 : 235–242. [Google Scholar]
  22. Kato R, Uetrecht J. Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes. Chem Res Toxicol 2017 ; 30 : 1327–1332. [PubMed] [Google Scholar]
  23. Oda S, Matsuo K, Nakajima A, et al. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol Lett 2016 ; 241 : 60–70. [PubMed] [Google Scholar]
  24. Kegel V, Pfeiffer E, Burkhardt B, et al. Subtoxic concentrations of hepatotoxic drugs lead to Kupffer cell activation in a human in vitro liver model: an approach to study DILI. Mediators Inflamm 2015 ; 2015 : 1–14. [Google Scholar]
  25. Ogese MO, Faulkner L, Jenkins RE, et al. Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci 2017 ; 158 : 76–89. [PubMed] [Google Scholar]
  26. Mak A, Kato R, Weston K, et al. Editor’s highlight: an impaired immune tolerance animal model distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI. Toxicol Sci 2018 ; 161 : 412–420. [PubMed] [Google Scholar]
  27. Kim SH, Naisbitt DJ. Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res 2016 ; 8 : 3. [PubMed] [Google Scholar]
  28. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1 * 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011 ; 29 : 667–673. [PubMed] [Google Scholar]
  29. Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017 ; 66 : 1154–1164. [Google Scholar]
  30. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012 ; 486 : 554–558. [PubMed] [Google Scholar]
  31. Schrey AK, Nickel-Seeber J, Drwal MN, et al. Computational prediction of immune cell cytotoxicity. Food Chem Toxicol 2017 ; 107 : 150–166. [PubMed] [Google Scholar]
  32. Ghattaoraya GS, Dundar Y, González-Galarza FF, et al. A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database 2016; 2016 : baw069. [PubMed] [Google Scholar]
  33. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014 ; 89 : 95–106. [PubMed] [Google Scholar]
  34. Whritenour J, Ko M, Zong Q, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 2017 ; 14 : 31–38. [PubMed] [Google Scholar]
  35. Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut 2016 ; 65 : 1555–1563. [Google Scholar]
  36. Benesic A, Rotter I, Dragoi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol 2018 ; 16 : 1488–94e5. [PubMed] [Google Scholar]
  37. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001 ; 14 : 694–701. [PubMed] [Google Scholar]
  38. Jaskiewicz K, Voigt H, Blakolmer K. Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J Toxicol Clin Toxicol 1996 ; 34 : 301–305. [Google Scholar]
  39. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002 ; 22 : 27–42. [Google Scholar]
  40. DeLeve LD, Kaplowitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995 ; 24 : 787–810. [PubMed] [Google Scholar]
  41. Schiodt FV, Lee WM, Bondesen S, et al. Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. Aliment Pharmacol Ther 2002 ; 16 : 707–715. [Google Scholar]
  42. Đakovic´-Švajcer K, Samojlik I, Raškovic´ A, et al. The activity of liver oxidative enzymes after single and multiple grapefruit juice ingestion. Exp Toxicol Pathol 1999; 51 : 304–8. [PubMed] [Google Scholar]
  43. Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 2005 ; 1 : 151–156. [PubMed] [Google Scholar]
  44. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008 ; 64 : 1147–1161. [Google Scholar]
  45. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013 ; 58 : 388–396. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.